|
Re:
|
Access
Pharmaceuticals, Inc. – File No.
333-149633
|
·
|
Details
of the issuance of the Series A Preferred Stock that is being registered
for resale, including the form of consideration paid, the dates of
acquisition, the number of underlying shares of common stock, the
conversion price per share, the market price, and the total profit
received upon conversion;
|
·
|
Details
of the gross proceeds received by the registrant in each private placement
transaction, and compensation of this number of the placement agent fees
paid to selling stockholders;
|
·
|
Discussion
of all payments to be made to selling shareholders in connection with the
private placement transactions, including placement agent fees, liquidated
damages, and dividends;
|
·
|
Details
of the total possible profit that the selling shareholders and their
affiliates could realize as a result of the conversion discount for the
securities underlying the warrants and options that they held prior to the
registrant’s issuance of Series A Preferred Stock;
and
|
·
|
Description
of the other securities transactions to which the registrant has been a
party along with the selling stockholders and their affiliates. (This
table should provide information regarding the date of the prior
securities transaction, the principal amount of the convertible
securities, the amount of common stock underlying the convertible
securities, the market price per share immediately prior to the
transaction, any placement agent fees paid, the number of shares in each
transaction that had been previously registered, and the number of shares
that had not been previously
registered.)
|